ProMab Biotechnologies. Inc 1 article published in JoVE Immunology and Infection A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells Biao Xi1, Robert Berahovich2, Hua Zhou2, Shirley Xu2, Yuehua Wei2, Jasper Guan2, Hizkia Harto2, Jian Guan2, Lijun Wu2, David Santa Ana1,3, Fabio Cerignoil1, Brandon Lamarche1, Yama A. Abassi1, Vita Golubovskaya2 1ACEA Biosciences, Inc, 2ProMab Biotechnologies. Inc, 3ACEA Therapeutics We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.
